Tag: manufacturing

LEHIGH VALLEY, Pa., June 25, 2026 /PRNewswire/ -- Air Products (NYSE: APD) will highlight its flash freezing solutions for specialty foods at the Summer Fancy...

Sponsorship builds on years of DENSO's support for the Guelph CommunityGUELPH, ON, June 25, 2026 /PRNewswire/ -- DENSO Manufacturing Canada, Inc. (DMCN), will co-sponsor...

ATLANTA, June 25, 2026 /PRNewswire/ -- Norfolk Southern Corporation (NYSE: NSC) will announce its second quarter 2026 financial results during a live conference call...

JellyFil discloses 2026 gummy supplement ingredient origins, cGMP manufacturing standards, caffeine content, and drug interaction guidance.

Haffner Energy is accelerating the execution of its roadmap with CORE100, H6 and its international developments.

Environmental, health, and safety solution is part of Veeva Quality Cloud and will deliver real-time insights and streamlined workflowsPLEASANTON, Calif., June 25, 2026 /PRNewswire/...

GrayMatter Robotics shows Physical AI removing six finishing automation constraints, from training cycles to cloud dependencies, in 20+ industries.

DELRAY BEACH, Fla., June 25, 2026 /PRNewswire/ -- According to MarketsandMarkets, "Polymethyl Methacrylate (PMMA) Market by Grade (General-Purpose, Optical), Form (Extruded Sheet, Cast Acrylic Sheet),...

Beam Global is relocating manufacturing from San Diego to Yuma, Arizona, reducing costs, improving margins, and supporting future growth.

Herbalife–IIT Madras Centre of Excellence aims to position India as a global leader in sustainable biomanufacturing and next-generation plant-derived health and wellness productsCHENNAI, India,...

NEWARK, Del., June 25, 2026 /PRNewswire/ -- According to a recent study by Future Market Insights (FMI), the global Rare Neurological Disease Treatment Market...

NEWARK, Del., June 25, 2026 /PRNewswire/ -- According to a recent study by Future Market Insights (FMI), the global Rare Neurological Disease Treatment Market...

CHENGDU, China, June 25, 2026 /PRNewswire/ -- On June 23, 2026, C-Ray Therapeutics (Chengdu) Co., Ltd. ("C-Ray Therapeutics") completed on-site inspections conducted by a panel...

DALLAS, June 24, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced the pricing of an underwritten public offering of 32,500,001 shares of its common stock at a price to the public of $6.00 per share and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase 833,333 shares of its common stock at an offering price of $5.999 per pre-funded warrant, in each case before underwriting discounts and commissions. All of the securities are being offered by Taysha. In addition, Taysha has granted the underwriters a 30-day option to purchase up to an additional 5,000,000 shares of common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds from the offering to Taysha are expected to be approximately $200.0 million, before deducting underwriting discounts and commissions and other offering expenses, excluding any exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on or about June 26, 2026, subject to customary closing conditions.